Date: October 1, 2026
Investment / Strategic Actions
Zydus Lifesciences Limited provided an update on its investment in Zydus Sunshine Lifesciences (Private) Limited ("Zydus Sunshine"). The company referenced its earlier intimation dated June 26, 2026, regarding the execution of a Share Subscription and Shareholders' Agreement ("SSSHA") with Sunshine Healthcare Lanka Limited ("Sunshine") and Zydus Sunshine.
The agreement involves subscribing to 50% of the total paid-up equity share capital of Zydus Sunshine ("Subscription Shares"). Post-subscription, Zydus Sunshine was intended to become a 50:50 joint venture between Zydus Lifesciences and Sunshine.
As of October 1, 2026, Zydus and Sunshine are still in the process of completing condition precedents of the SSSHA. Consequently, both parties have mutually decided to extend the date of closing as per the terms and conditions of the SSSHA.
The companies executed a letter on October 1, 2026, to formally extend the completion date. The transaction is now expected to be completed by December 2026.
Signature Details
The disclosure was signed by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCSS7063) of Zydus Lifesciences Limited on October 1, 2026.